Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Drug use evaluation of cefepime in the first affiliated hospital of Bengbu medical college: a retrospective and prospective analysis

Authors: Shi Qingping, Ding Feng, Sang Ran, Liu Yan, Yuan HaoYu, Yu Meiling

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Cefepime is a fourth generation cephalosporin antimicrobial. Its extended antimicrobial activity and infrequent tendency to engender resistance make it popular for the treatment of infections. However, proper use of cefepime has not been studied adequately. In this study, we used a retrospective cohort and a prospective cohort to evaluate the usage pattern, adverse effects and cost-effectiveness of cefepime by conducting a drug use evaluation (DUE) program in the First Affiliated Hospital of Bengbu Medical College, Anhui, China.

Methods

The DUE criteria for cefepime were established by applying literature review and expert consultation, an effective method to promote interventions that will improve patient outcomes and the cost-effectiveness of drug therapy. According to the criteria, we performed a cross-sectional retrospective (cycle A) study on 96 hospitalized patients who received cefepime treatment and a prospective (cycle B) study on 111 hospitalized patients with cefepime treatment intervention. After identifying problems with usage and completing a cefepime use evaluation for cycle A, 2 months of educational intervention among professionals were given and a more effective and rational system of cefepime use was set up. During the 2 months, the lectures were arranged and attendance of prescribers was required.

Results

The data from cycle A showed that the biggest problem was irrational prescription of cefepime; bacterial culture and drug sensitivity tests for cefepime were also not carried out. Following 2 months of educational intervention among professionals, the results for cycle B showed that the correct indication rate was 94.59%, compared with 84.38% in cycle A. Use of bacterial culture and sensitivity tests also improved, by 88.29% in cycle B compared with 65.22% in cycle A. Compared with cycle A, the significantly improved items (P < 0.05) in cycle B were blood examination, liver function monitoring, renal function monitoring, dose and duration, dosing frequency and correct medication combinations.

Conclusions

Cefepime can be used appropriately for the right indications and in a cost-effective way for the majority of patients through educational intervention, including the special precautions that must be followed for appropriate dosing frequency and duration. DUE programs will become one model of hospital pharmacy care and part of the plan for continuous improvements to the quality of health care in China.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lei J, Wang YS: Cefepime. World Pharm. 1996, 17: 354-358. Lei J, Wang YS: Cefepime. World Pharm. 1996, 17: 354-358.
2.
go back to reference Zhang P: New broad-spect rum antibiotics—cefepime. New Drugs Clin Rem (in Chinese). 1995, 14: 164-166. Zhang P: New broad-spect rum antibiotics—cefepime. New Drugs Clin Rem (in Chinese). 1995, 14: 164-166.
3.
go back to reference Lu HZ, Weng XH, Pang MY: Phase IV trials of cefepime in treat-ment of various moderate or severe bacterial infections. Chin J New Drugs Clin Remedies. 2002, 21: 268-270. Lu HZ, Weng XH, Pang MY: Phase IV trials of cefepime in treat-ment of various moderate or severe bacterial infections. Chin J New Drugs Clin Remedies. 2002, 21: 268-270.
4.
go back to reference Li SX, Ren B: Clinical application of cefepime. New medicine. 2004, 35: 49-50. Li SX, Ren B: Clinical application of cefepime. New medicine. 2004, 35: 49-50.
5.
go back to reference Brodie DC, Smith WE, Hlynka JN: Model for drug usage review in a hospital. Am J Hosp Pharm. 1977, 34: 251-PubMed Brodie DC, Smith WE, Hlynka JN: Model for drug usage review in a hospital. Am J Hosp Pharm. 1977, 34: 251-PubMed
6.
go back to reference ASHP: ASHP guidelines on the pharmacist’s role in drug-use evaluation. Am J Hosp Pharm. 1988, 45: 385- ASHP: ASHP guidelines on the pharmacist’s role in drug-use evaluation. Am J Hosp Pharm. 1988, 45: 385-
7.
go back to reference Woods M: Criteria for use of cefepime in adults: American Society of Hospital Pharmacists. Am J Health Syst Pharm. 1994, 51: 531- Woods M: Criteria for use of cefepime in adults: American Society of Hospital Pharmacists. Am J Health Syst Pharm. 1994, 51: 531-
8.
go back to reference World Health Organization: Introduction to drug utilization research. 2003, Norway: Printed in Oslo, 1-84. World Health Organization: Introduction to drug utilization research. 2003, Norway: Printed in Oslo, 1-84.
9.
go back to reference Bae JP: Project Officer Health Care Financing Administration Office of Research and Demonstrations. Evaluation of Drug Use Review Demonstration Projects, Project Officer Health Care Financing Administration Office of Research and Demonstrations. 1998, HCFA Evaluation of Drug Review Projects-Final report, 1-376. http://www.abtassociates.com/reports/19986221703451.pdf, Bae JP: Project Officer Health Care Financing Administration Office of Research and Demonstrations. Evaluation of Drug Use Review Demonstration Projects, Project Officer Health Care Financing Administration Office of Research and Demonstrations. 1998, HCFA Evaluation of Drug Review Projects-Final report, 1-376. http://​www.​abtassociates.​com/​reports/​19986221703451.​pdf,
10.
go back to reference Wu TC, Fu Y: Brief introduction of drug use evaluation. Chin J Pharmaco Epidemiol. 2005, 14: 46-49. Wu TC, Fu Y: Brief introduction of drug use evaluation. Chin J Pharmaco Epidemiol. 2005, 14: 46-49.
13.
go back to reference Raveh D, Muallem-zilcha E, Greenberg A: Prospective drug utilization evaluation of threebroad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. Q J Med. 2006, 99: 397-406. 10.1093/qjmed/hcl050.CrossRef Raveh D, Muallem-zilcha E, Greenberg A: Prospective drug utilization evaluation of threebroad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. Q J Med. 2006, 99: 397-406. 10.1093/qjmed/hcl050.CrossRef
14.
go back to reference Ma Y, Li JY, Hu CQ: Study on the antimicrobial activities of cefepime against gram-negative bacteria in vitro from 1999 to 2002 in China. Chin J Lab Med. 2004, 27: 747-751. Ma Y, Li JY, Hu CQ: Study on the antimicrobial activities of cefepime against gram-negative bacteria in vitro from 1999 to 2002 in China. Chin J Lab Med. 2004, 27: 747-751.
15.
go back to reference Nasir Tajure W, Oumer S: Drug use evaluation of ciprofloxacin in teriary settding hospital. J Med Pharm Sci. 2011, 1: 17-23. Nasir Tajure W, Oumer S: Drug use evaluation of ciprofloxacin in teriary settding hospital. J Med Pharm Sci. 2011, 1: 17-23.
16.
go back to reference Wasam Liaqat T, Mehreen F, Fatima A: Drug Utilization Evaluation of vancomycin in Teaching Hospitals of Lahore. J Pharm Sci Res. 2012, 4: 1728-1733. Wasam Liaqat T, Mehreen F, Fatima A: Drug Utilization Evaluation of vancomycin in Teaching Hospitals of Lahore. J Pharm Sci Res. 2012, 4: 1728-1733.
17.
go back to reference Wang HL, Ma LJ, Liu XW: Drug Resistance the Fourth Generation Cephalosporin Cefepime and Its Risk Factors. Evaluation Analysis Drug-use Hospitals Chin. 2010, 10: 1092-1094. Wang HL, Ma LJ, Liu XW: Drug Resistance the Fourth Generation Cephalosporin Cefepime and Its Risk Factors. Evaluation Analysis Drug-use Hospitals Chin. 2010, 10: 1092-1094.
18.
go back to reference Yinnon AM: Whither infectious diseases consultations. Analysis of 14,005 consultations from a 5-year period. Clin Infect Dis. 2001, 33: 1661-1667. 10.1086/323760.CrossRefPubMed Yinnon AM: Whither infectious diseases consultations. Analysis of 14,005 consultations from a 5-year period. Clin Infect Dis. 2001, 33: 1661-1667. 10.1086/323760.CrossRefPubMed
19.
go back to reference Wang Q, Liu YP, Han Q: The ADR review of cefepime. Tianjin Pharmacy. 2009, 21: 52-55. Wang Q, Liu YP, Han Q: The ADR review of cefepime. Tianjin Pharmacy. 2009, 21: 52-55.
20.
go back to reference Jin SP, Li CJ: Drug adverse reaction of cefepime. Chin J Misdiagn. 2009, 9: 7039-7040. Jin SP, Li CJ: Drug adverse reaction of cefepime. Chin J Misdiagn. 2009, 9: 7039-7040.
21.
go back to reference Navarro R: Drug Utilization Review Strategies. Managed Care Pharm Prac. 2008, 8: 215-229. Navarro R: Drug Utilization Review Strategies. Managed Care Pharm Prac. 2008, 8: 215-229.
22.
go back to reference Bailey TC, Troy McMullin S: Using information systems technology to improve antibiotic prescribing. Crit Care Med. 2001, 29: 87-91. 10.1097/00003246-200104001-00006.CrossRef Bailey TC, Troy McMullin S: Using information systems technology to improve antibiotic prescribing. Crit Care Med. 2001, 29: 87-91. 10.1097/00003246-200104001-00006.CrossRef
Metadata
Title
Drug use evaluation of cefepime in the first affiliated hospital of Bengbu medical college: a retrospective and prospective analysis
Authors
Shi Qingping
Ding Feng
Sang Ran
Liu Yan
Yuan HaoYu
Yu Meiling
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-160

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine